Advertisement!
Author Information Pack
Editorial Board
Submit article
Special Issue
Editor's selection process
Join as Reviewer/Editor
List of Reviewer
Indexing Information
Most popular articles
Purchase Single Articles
Archive
Free Online Access
Current Issue
Recommend this journal to your library
Advertiser
Accepted Articles
Search Articles
Email Alerts
FAQ
Contact Us
Pediatrics Education and Research

Volume  4, Issue 2, May-Aug 2016, Pages 107-108
 

Case Report

Fanconi’s Anaemia

Ninza Rawal*, Sunil Mhaske**, Liza Bulsara*

*Resident, **Professor & Head, Dept. of Paediatrics, PDVVPF’s Medical College and Hospital, Vilad Ghat, Ahmednagar, Maharashtra 414111.

Choose an option to locate / access this Article:
90 days Access
Check if you have access through your login credentials.        PDF      |
|

Open Access: View PDF

DOI: DOI: https://dx.doi.org/10.21088/per.2321.1644.4216.13

Abstract

 Fanconi anaemia (FA) is a very rare genetic disease with an incidence estimated at 1 per 130,000 births. FA is the result of a genetic defect in a cluster of proteins responsible for DNA repair As a result, the majority of FA patients develop cancer, most often Acute Myelogenous Leukemia, and 90% develop Bone Marrow Failure by age 40. About 60–75% of FA patients have congenital defects, commonly short stature, abnormalities of the skin, arms, head, eyes, kidneys, and ears, and developmental disabilities. Around 75% of FA patients have some form of endocrine problem, with varying degrees of severity. Median age of death is around 30­35 years. Treatment with androgens and hematopoietic (blood cell) growth factors can help bone marrow failure temporarily, but the long­term treatment is Bone Marrow Transplant if a donor is available. 

Keywords: Fanconi; Anaemia; Bone Marrow Failure.


Corresponding Author : Ninza Rawal*